Pepdexpepdex
Stack
← All compounds

Emoxypine

Mexidol / emoxypine succinate · Antioxidant / anxiolytic (Russian pharmaceutical)

Research reference only. Pepdex does not sell, supply or track this compound, and nothing here is guidance to use it — this page exists so the evidence and the risks are visible.

What it is

A Russian prescription drug (Mexidol) used there for anxiety, stroke recovery, and "neuroprotection" — structurally related to vitamin B6, pitched in Western nootropic markets as a gentle anxiolytic without sedation.

How it works

Emoxypine (marketed as Mexidol) is a Russian pharmaceutical — 2-ethyl-6-methyl-3-hydroxypyridine succinate — described as a membrane-protecting antioxidant. The proposed mechanism combines free-radical scavenging with effects on membrane fluidity and on succinate-linked mitochondrial energy production, plus modulation of GABA and benzodiazepine receptor complexes that would account for its anxiolytic reputation. It is worth noting the compound is usually discussed under two different names, which obscures that the Mexidol trials and the "emoxypine" supplement being sold are meant to be the same thing.

What human evidence shows

A substantial Russian clinical literature that Western review standards struggle with: many trials, mostly small, mostly unblinded, essentially none replicated outside the country — the same evidentiary shape as bromantane (see that entry). By this app's tiering it grades Limited: real drug, real usage history, unverifiable claims.

The studies, one by one

  • It is an approved prescription medicine in Russia with a substantial clinical literature there, used in stroke, cognitive impairment, anxiety and several other indications.
  • That literature is Russian-language, largely from within the same research community, and has not been independently replicated in Western trials. It is not approved anywhere in the West.
  • The breadth of claimed indications is itself a signal worth reading carefully — a compound reported effective across stroke, anxiety, glaucoma, cognition and cardiac conditions is either remarkable or reflects a research environment with different evidentiary standards.
  • NONE SHOWN in any Western randomised trial, because none exists.
  • Tolerability within the available literature is described as good, which is weak evidence when the literature is unreplicated.

Half-life and how long it lasts

Available in oral and injectable forms in Russia. Human pharmacokinetics outside that literature are poorly characterised. What is sold in the West is research-chemical or grey-market supply of unverified identity rather than the approved pharmaceutical, and for the injectable form that raises sterility concerns on top of purity ones.

Risks

Russian prescribing lists mild effects (nausea, drowsiness at higher exposures), and its decades of clinical use there are weak-but-real safety evidence. The practical risks are product quality outside its home market and the general problem of self-treating anxiety on evidence with limited independent replication and uncertain applicability under modern trial standards.

Who should never touch it

  • Anyone using an injectable grey-market product, where sterility is unverifiable
  • Anyone pregnant or breastfeeding
  • Anyone taking sedatives, given the claimed receptor activity
  • Anyone treating a serious condition with it in place of treatment that has been independently evaluated

Interactions worth knowing

  • No characterised interaction profile exists in Western literature.
  • Benzodiazepines and other sedatives, on mechanistic grounds given the claimed receptor modulation.
  • Blood-pressure medication, given reported cardiovascular effects.

What a clinician would watch

  • There is no established Western monitoring guidance, since no Western regulator has assessed it.
  • Blood pressure, given reported cardiovascular effects in the Russian literature.
  • Any injection-site reaction or infection for anyone using an injectable grey-market product, which is the highest practical risk here.
  • Whether the product is what it claims — the same compound is sold under two names, which makes verification harder rather than easier.

What stopping looks like

No withdrawal syndrome is described in the available literature. Since no independently replicated evidence establishes a benefit, there is no established effect to lose on stopping.

Myth vs evidence

“It is clinically proven because it is an approved medicine.”

It is approved in one regulatory system on a literature no independent group has reproduced. Approval standards differ substantially between regulators.

“It works for a wide range of conditions.”

That breadth is a reason for more scepticism rather than less. Compounds reported effective across many unrelated indications usually turn out to be effective in few.

“Decades of use in Russia proves safety.”

Long availability in one country with limited pharmacovigilance is weak evidence, and it says nothing about the unverified product sold in the West.

Legal status

US: unapproved, unscheduled; prescription pharmaceutical in Russia/CIS.

Research on this compound

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

Evidence base

A366 research papers
substantial literature

Strong human evidence: either a phase 3 or 4 trial report alongside review-level evidence, or ten or more randomised controlled trial reports.

phase 3/4
0
randomised
40
reviews
2
human trials
70

Counts are of published papers, not distinct trials, and they nest rather than add up: PubMed files every randomised trial as a clinical trial too. They measure how much research exists — not whether this works or is safe for you.

Research (12)

Turn Emoxypine into a plan that's yours

The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.

  • ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
  • ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
  • ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Become a member, from $4.99/week

Cancel anytime · or save with $59.99/yr · Coach + Stack included

Where next

Every compound in the catalogThe full non-peptide index, with evidence grades.→The peptide indexInjectable peptides, half-lives and what trials used.→Spotting a scam vendorRed flags, COA checks and what traceability looks like.→